Enhancing patient safety with AI
Why patient safety strategies need to change
Ensuring the quality and safety of a medicinal product is both a moral and a regulatory requirement across the biopharmaceutical (biopharma) value chain. Pharmacovigilance (PV) is a crucial mechanism for providing evidence to the biopharma industry and regulators of the long-term safety profile of medicines. Meanwhile, patient support programmes (PSPs) help patients manage their medication and disease outcomes more effectively and, in certain circumstances, can improve equitable access and provide early safety signals. A rising incidence of post-launch adverse event reports (AERs) and increasing expectation of more personalised, preventative, predictive and participatory (4P) medicine has coincided with advances in artificial intelligence (AI) technologies and data analytics. This conjunction increases the potential for post-launch strategies to increase safety, improve equity and enhance patient engagement and experience.
Improving patient support is a critical step in the biopharma value chain
As we highlighted in our 2019 overview report, Intelligent biopharma: Forging the links across the value chain, the pace and scale of scientific innovation are improving patient engagement and experience, creating new business models and transforming the biopharma industry. We concluded that digital transformation, with advanced technologies such as AI, was the next logical step in the evolution of biopharma. This could enable innovation in new products and services and improve customer engagement and process efficiency.1
This is the sixth and final report in our series on the role of AI in driving biopharma’s digital transformation. It explores the potential of AI to improve the last step in the value chain – specifically post-market PV and PSPs (figure 1). The overarching aim of the report is to explore how AI can improve patient outcomes by detecting real-time adverse events (AEs) more efficiently and effectively; and how it can be applied to interoperable health data, generated within PSPs to improve the remote monitoring of patients and deliver safer, more personalised and precise treatment options promptly.
To read the full article by Medilink Midlands Patron Deloitte LLP, please click here
